NR 566 Week 4 | Latest Update | 2024/2025 | Graded A+

NR 566 Week 4 | Latest Update | 2024/2025 | Graded A+ Baseline data for Lorcaserin Rule out valvular disorders and pulmonary hypertension baseline data for orlistat None noted Baseline data for phentermine Cardiac assessment Baseline data: Liraglutide HB A1C, lipids, renal function Assessment of the one administering the injection DEA schedules of drugs to treat obesity: bupropion/naltrexone (contrave) Not a controlled drug DEA schedules of drugs to treat obesity: diethylpropion (generic) Scheduled IV DEA schedules of drugs to treat obesity: liraglutide (saxenda) Not a controlled drug DEA schedules of drugs to treat obesity: lorcaserin (belviq, Belviq XR) Schedule IV DEA schedules of drugs to treat obesity: orlistat (alli and xenical) Not a controlled drug DEA schedules of drugs to treat obesity: Phentermine (Adipex-P, Lomaira) Schedule IV DEA schedules of drugs to treat obesity: Phentermine/Topiramate (Qsymia) Schedule IV Lorcaserin (Belviq) weight loss drug Lorcaserin (Belviq) Drug interactions LOR is a 2D6 inhibitor so avoid SSRIs, SNRIs, TCAs, MAOIs, triptans, etc Could lead to Serotonin syndrome and increased risk of valve issues Lorcaserin adverse effects HA, back pain, decrease lymphocytes and URIs, hypoglycemia in diabetics